-transparent.png){kind=logo}
The adenosine deaminase (ADA) inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), at low concentrations (less than 10 microM), enhances the inhibitory activity of adenosine against lymphocyte-mediated cytolysis (LMC) without itself being inhibitory. At higher concentrations, EHNA alone is inhibitory to LMC with an IC50 of 160 microM. This inhibition is reversible upon washout, appears to affect an early stage of the lytic process, and does not appear to involve changes in basal levels of cyclic AMP (cAMP), ribonucleoside 5'-triphosphate pool sizes, S-adenosylhomocysteine levels, or protein carboxymethylation. EHNA does enhance the cAMP response of cytolytic lymphocytes (CL) to activators of adenylate cyclase such as prostaglandin E1. EHNA inhibits lymphocyte high-affinity cAMP phosphodiesterase at immunosuppressive levels, exhibiting hyperbolic mixed-type inhibition (Ki = 83 microM, alpha = 0.47, beta = 0.18). Whereas inhibition of intralymphocytic ADA is complete at low concentrations (less than 25 microM) of EHNA, inhibition of LMC and intralymphocytic cAMP phosphodiesterase increases linearly with EHNA concentration to at least 200 microM. The presence of 200 microM EHNA during the centrifugation of mixtures of CL and EL4 leukemia target cells leads to increased CL cAMP levels. 2'-Deoxycoformycin, a more potent ADA inhibitor than EHNA, is not inhibitory to LMC and shows none of these cAMP-related effects. These results suggest that CL-target cell contact stimulates adenylate cyclase in the CL and that EHNA inhibits LMC due to its enhancement of this target cell-stimulated elevation of cAMP.
G S Duncan, and
G Wolberg, and
C J Schmitges, and
R D Deeprose, and
T P Zimmerman
July 1995,
Molecular pharmacology,
G S Duncan, and
G Wolberg, and
C J Schmitges, and
R D Deeprose, and
T P Zimmerman
September 1995,
Cellular signalling,
G S Duncan, and
G Wolberg, and
C J Schmitges, and
R D Deeprose, and
T P Zimmerman
June 1978,
Journal of neurochemistry,
G S Duncan, and
G Wolberg, and
C J Schmitges, and
R D Deeprose, and
T P Zimmerman
September 1992,
Biochemistry,
G S Duncan, and
G Wolberg, and
C J Schmitges, and
R D Deeprose, and
T P Zimmerman
February 1982,
Biochemical pharmacology,
G S Duncan, and
G Wolberg, and
C J Schmitges, and
R D Deeprose, and
T P Zimmerman
March 1982,
Biochemical pharmacology,
G S Duncan, and
G Wolberg, and
C J Schmitges, and
R D Deeprose, and
T P Zimmerman
February 1996,
The Journal of pharmacology and experimental therapeutics,
G S Duncan, and
G Wolberg, and
C J Schmitges, and
R D Deeprose, and
T P Zimmerman
March 1984,
Journal of medicinal chemistry,
G S Duncan, and
G Wolberg, and
C J Schmitges, and
R D Deeprose, and
T P Zimmerman
January 1979,
Biochemical pharmacology,
G S Duncan, and
G Wolberg, and
C J Schmitges, and
R D Deeprose, and
T P Zimmerman
January 1980,
Drug metabolism and disposition: the biological fate of chemicals,
